Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Sorrento's COVID-19 Main Protease Inhibitor Neutralizes Omicron

Sorrento Therapeutics Inc's (NASDAQ:SRNE) late-stage preclinical Mpro inhibitor, STI-1558, effectively inhibits omicron virus entry and replication in cell-based assays.

  • In VeroE6 cells challenged with omicron variant, STI-1558 alone (without efflux inhibitor) showed significant antiviral activity with an EC50 value of 360 nM, equivalent to that seen against the Delta variant (EC50 value, 370 nM). 
  • Related: Sorrento Therapeutics' COVID-19 Antibody Works Against Omicron Variant.
  • In an omicron S protein-mediated pseudovirus entry assay, STI-1558 effectively inhibited pseudovirus entry into cells, whereas EUA-approved Pfizer Inc's (NYSE:PFE) nirmatrelvir (Paxlovid) showed no inhibition. 
  • STI-1558 showed improved human liver metabolic stability compared to nirmatrelvir, and its oral bioavailability does not depend on the ritonavir co-administration. 
  • Without the need to co-administer Ritonavir, STI-1558 potentially avoids significant adverse drug-drug interactions.
  • Price Action: SRNE shares are down 0.35% at $2.87 during the market session on the last check Friday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.